For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Synthetic peptide corresponding to residues in human CD13
Produced using Abcam's RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5, 675, 063 and/or 7, 429, 487.
Our Abpromise guarantee covers the use of ab108310 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 110 kDa.|
|IP||1/10 - 1/100.|
|IHC-P||1/250 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
|ICC||1/250 - 1/500.|
Lane 1: Wild type HAP1 whole cell lysate (20 µg)
Lane 2: Empty
Lane 3: CD13 (KO) whole cell lysate (20 µg)
Lane 4: Empty
Lane 5: HeLa whole cell lysate (20 µg)
Lanes 1 - 5: Merged signal (red and green). Green - ab108310 observed at 160 kDa. Red - loading control, ab18058, observed at 130 kDa.
ab108310 was shown to recognize CD13 when CD13 knockout samples were used, along with additional cross-reactive bands. Wild-type and CD13 knockout samples were subjected to SDS-PAGE. Ab108310 and ab18058 (Mouse anti Vinculin loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/10000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.